<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01796717</url>
  </required_header>
  <id_info>
    <org_study_id>CIH-WDH-201205001</org_study_id>
    <nct_id>NCT01796717</nct_id>
  </id_info>
  <brief_title>Optimizing Dosing Regimen of Piperacillin/Tazobactam for Nosocomial Pneumonia</brief_title>
  <official_title>Optimizing Dosing Regimen of Piperacillin/Tazobactam, Prolonged Infusion vs. Regular Infusion, Every 6 Hours, for Nosocomial Pneumonia in ICU Caused by Susceptible Pathogens With Higher MIC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To observe clinical and bacteriologic responses of different regimens of
           piperacillin/tazobactam (4.5g q6h, prolonged or intermittent infusion) for treatment of
           nosocomial pneumonia.

        2. To describe the pharmacokinetic profile of piperacillin/tazobactam (4.5g q6h, prolonged
           or intermittent infusion) in patients with nosocomial pneumonia.

        3. To assess the safety profiles of piperacillin/tazobactam 4.5g q6h, prolonged or
           intermittent infusion in patients with nosocomial pneumonia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enrolled patients will be randomized into therapeutic or controlled group. Controlled group
      will receive piperacillin/tazobactam of 4.5g Q6h, intermittent infusion for 30 minutes.
      Therapy group will receive piperacillin/tazobactam of 4.5g Q6h, prolonged infusion for 4
      hours. The duration is 7-14 days.

      Two sets of blood cultures (for aerobic and anaerobic culture) were obtained before the study
      and post-treatment period if first blood culture is positive. Cultures from the lower
      respiratory tract infection were obtained before (within 48 h) the study and on the last day
      of therapy. The lower respiratory tract specimens obtained either by endotracheal aspiration,
      bronchoalveolar lavage (BAL), a protected brush procedure (PBP) or as sputum were required to
      show &gt; 25 polymorphonuclear cells and &lt; 10 squamous epithelial cells per field (at 100×
      magnification).

      The plasma concentration of piperacillin and tazobactam will be determined by LC/MS/MS
      method. The QC samples will also be analyzed simultaneously with each run for the method
      stability testing, according to the laboratory standard procedure.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Extension of the Piperacillin / tazobactam infusion time effect evaluation</measure>
    <time_frame>2 weeks</time_frame>
    <description>To observe clinical and bacteriologic responses of different regimens of piperacillin/tazobactam (4.5g q6h, prolonged or intermittent infusion) for treatment of nosocomial pneumonia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reducing antibiotic resistance</measure>
    <time_frame>2 weeks</time_frame>
    <description>To describe the pharmacokinetic profile of piperacillin/tazobactam (4.5g q6h, prolonged or intermittent infusion) in patients with nosocomial pneumonia.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Nosocomial Pneumonia</condition>
  <arm_group>
    <arm_group_label>C Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Controlled group will receive piperacillin/tazobactam of 4.5g Q6h, intermittent infusion for 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Therapy group will receive piperacillin/tazobactam of 4.5g Q6h, prolonged infusion for 4 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C Group</intervention_name>
    <description>Controlled group will receive piperacillin/tazobactam of 4.5g Q6h, intermittent infusion for 30 minutes</description>
    <arm_group_label>C Group</arm_group_label>
    <other_name>nosocomial pneumonia</other_name>
    <other_name>MIC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E Group</intervention_name>
    <description>Therapy group will receive piperacillin/tazobactam of 4.5g Q6h, prolonged infusion for 4 hours</description>
    <arm_group_label>E Group</arm_group_label>
    <other_name>nosocomial pneumonia</other_name>
    <other_name>MIC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, aged 18 to 70 years old.

          2. Inpatients with nosocomial pneumonia or bacteremia.

             i. Diagnosis of nosocomial pneumonia

               1. Chest radiographic infiltrate that is new or progressive.

               2. At least two or more of the following clinical findings suggesting infection.

                    -  New onset of fever, oral temperature T&gt;38.3℃ or T&lt;36℃

                         -  Purulent sputum

                              -  WBC &gt; 12×10^9/L or &lt;4×10^9/L, or band form &gt;10%

                                   -  PaO2/FIO2&lt;240mmHg

             ii. Diagnosis of bacteremia: Positive blood culture and the isolated bacterial strain
             are considered to be infection cause.

          3. Patients are infected by piperacillin-tazobactam susceptible pathogen with MIC=4, 8 or
             16mg/L.

        Exclusion Criteria:

          1. The patients who received systematic antibacterial treatment more than 48 hours before
             enrollment and have clinical response.

          2. Severe pyemia with hypotension or/and evidences of failure of organic function (shock:
             systolic pressure &lt; 90mmHg or diastolic pressure &lt; 60mmHg, requiring more than 4 hours
             of administration of vasopressor(s)；renal impairment: urine volume &lt; 20 ml∕h or &lt; 80
             ml∕4h after excluded any other potentials, acute renal failure need dialysis, CLcr&lt;40
             mL/min).

          3. Documented infection caused by pathogens beyond the antibacterial spectrum of
             piperacillin/tazobactam.

          4. Previously diagnosed condition which tend to mimic or complicate the course and
             evaluation of the infectious process, e.g. bronchial obstruction, obstructive
             pneumonia, activate pulmonary malignancy, pulmonary abscess, empyema and active
             tuberculosis, which might interfere the course of the infectious disease and
             evaluation of the disease.

          5. History of allergy to penicillins.

          6. Pregnancy or breast-feeding women.

          7. Any conditions investigator considered might increase the risk of patients or
             interfere study results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wang Donghao, Chief</last_name>
    <role>Study Chair</role>
    <affiliation>Tianjin Medical University Cancer Institute and Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wang Donghao, chief</last_name>
    <phone>022-23340123</phone>
    <phone_ext>1021</phone_ext>
    <email>donghaow@medmail.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>TianjinCIH</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wang Donghao, Chief</last_name>
      <phone>022-23340123</phone>
      <phone_ext>1021</phone_ext>
      <email>donghaow@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Yang Yang, resident</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>lv yang, resident</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>TianjinCIH</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wang Donghao, Chief</last_name>
      <phone>022-23340123</phone>
      <phone_ext>1021</phone_ext>
      <email>donghaow@medmail.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Roberts JA, Kirkpatrick CM, Roberts MS, Dalley AJ, Lipman J. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents. 2010 Feb;35(2):156-63. doi: 10.1016/j.ijantimicag.2009.10.008. Epub 2009 Dec 16.</citation>
    <PMID>20018492</PMID>
  </reference>
  <reference>
    <citation>Wang H, Chen M, Ni Y, Liu Y, Sun H, Yu Y, Yu X, Mei Y, Liu M, Sun Z, Chu Y, Hu Z, Huang X. Antimicrobial resistance among clinical isolates from the Chinese Meropenem Surveillance Study (CMSS), 2003-2008. Int J Antimicrob Agents. 2010 Mar;35(3):227-34. doi: 10.1016/j.ijantimicag.2009.11.010. Epub 2010 Jan 4.</citation>
    <PMID>20047820</PMID>
  </reference>
  <reference>
    <citation>Lorente L, Jiménez A, Martín MM, Iribarren JL, Jiménez JJ, Mora ML. Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion. Int J Antimicrob Agents. 2009 May;33(5):464-8. doi: 10.1016/j.ijantimicag.2008.10.025. Epub 2009 Jan 15.</citation>
    <PMID>19150225</PMID>
  </reference>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2012</study_first_submitted>
  <study_first_submitted_qc>February 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2013</study_first_posted>
  <last_update_submitted>February 14, 2016</last_update_submitted>
  <last_update_submitted_qc>February 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Piperacillin/tazobactam</keyword>
  <keyword>MIC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Penicillanic Acid</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Piperacillin, tazobactam drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

